Fludarabine (phosphate) [75607-67-9]

Cat# HY-B0028-1ml

Size : 10mM/1mL

Brand : MedChemExpress

Request more information

Contact local distributor :


Phone : +1 850 650 7790

Description

Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

Cellular Effect
Cell Line Type Value Description References
HeLa IC50
2 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human M-HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human M-HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
HL-60 IC50
0.09 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
K562 IC50
0.4 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
KG-1 IC50
0.15 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human KG1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human KG1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
MCF7 IC50
0.13 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
MOLT-3 IC50
0.95 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human MOLT3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human MOLT3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
Raji IC50
0.4 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human Raji cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human Raji cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
Skut1B IC50
6 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human SK-UT-1B cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human SK-UT-1B cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
ZR-75-1 IC50
0.6 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human ZR-75-1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human ZR-75-1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
In Vitro

Fludarabine phosphate significantly reduces the cell viability in a dose-dependent manner. Fludarabine phosphate exhibits no effect in all tested concentrations when combined with either PBS or control vector, ACE-GFP. Fludarabine phosphate causes a significant decrease in cell viability for 24 h after exposure to ACE-PNP when compared to PBS and ACE-GFP at concentrations of 2.5, 5 and 10 μg/mL[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (273.82 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 5 mg/mL (13.69 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7382 mL 13.6908 mL 27.3815 mL
5 mM 0.5476 mL 2.7382 mL 5.4763 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  phosphate buffer Saline

    Solubility: 20 mg/mL (54.76 mM); Clear solution; Need ultrasonic

  • Protocol 2

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.85 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 18.33 mg/mL (50.19 mM); Clear solution; Need ultrasonic

Purity & Documentation
References

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
HY-B0069-1ml
 10mM/1mL 
40340012-2
 25g